AAPS–FIP Summary Workshop Report: Pharmacogenetics in Individualized Medicine: Methods, Regulatory, and Clinical Applications
Journal Title: The AAPS Journal - Year 2009, Vol 11, Issue 2
Abstract
The workshop “Pharmacogenetics in Individualized Medicine: Methods, Regulatory, and Clinical Applications” was held November 15–16, 2008 in Atlanta, Georgia, USA. This workshop provided an opportunity for pharmaceutical scientists, clinical practitioners, clinical laboratory scientists, and FDA to discuss methods, regulatory, and the application of pharmacogenetics in clinical practice and drug discovery. Key highlights of the workshop were: (a) the use of genetic information in individualized medicine has significant potential in advancing drug development and human health by optimizing drug response, drug efficacy, and preventing adverse drug reactions; (b) various barriers exist preventing the advance of the individualized medicine in the society, industry, and clinical practice; and (c) the barriers may be overcome by integrated approaches; the education of researchers, clinical practitioners, and patients and fostering interactive communication among stakeholders. By targeting the AAPS audience, this workshop was one step among many steps that AAPS–FIP is intending to take towards removing the barriers to widespread uptake of pharmacogenetics in drug discovery and clinical practice.
Authors and Affiliations
Majid Moridani, Anke-Hilse Maitland-van der Zee, Hitoshi Sasaki, Ross McKinnon, Lawrence Fleckenstein, Vinod P. Shah
Keywords
Related Articles
- EP ID EP681472
- DOI 10.1208/s12248-009-9097-0
- Views 63
- Downloads 0
Wet granulation fine particle ethylcellulose tablets: Effect of production variables and mathematical modeling of drug release
In the present study, the applicability of fine particle ethylcellulose (FPEC) to produce matrix tablets by a wet granulation technique was evaluated. The effect of various formulation and process variables, such as FPEC...
Ligand Binding Assays in the 21st Century Laboratory: Platforms
A high level of precision is required to generate reproducible bioanalytical results for the measurement of drug, biomarker concentrations, and detection of immunogenic responses. Precision for LBAs analytical assays use...
Strategic Biomarkers for Drug Development in Treating Rare Diseases and Diseases in Neonates and Infants
There are similar challenges in developing a product designed to treat patients with a rare disease and drugs to treat critically ill neonates and infants. Part of the challenge in developing such products as well as ide...
Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates
Bioequivalence Requirements in the European Union: Critical Discussion
The aim of the present paper is to summarize the revised European Union (EU) Guideline on the Investigation of Bioequivalence and to discuss critically with respect to previous European requirements and present US Food a...